



IN THE CLAIMS:

1. (Cancelled)



2. (Currently amended) The method of claim 5 wherein the pharmaceutical agent comprises a compound of formula (Ia):



wherein R<sup>9</sup> is an alkyl group having 1-4 C atoms which, optionally, are substituted with halogen or replaced by halogen;

or a pharmaceutically acceptable salt thereof.


3. (Currently amended) The method of claim 5 wherein the pharmaceutical agent comprises a compound of formula (III):




or a pharmaceutically acceptable salt thereof.

4. (Cancelled)

5. (Currently amended) A method for a chemotherapeutic treatment of a neuropathy characterized by application to a patient in need thereof of from 1-100 mg/day of a pharmaceutical agent comprising a compound of formula (I):



—(I)—



(I)

in which

$R^1$  =  $C_{1-6}$ alkyl, optionally substituted with halogen,

$R^2$  = hydrogen or  $C_{1-4}$ alkyl, optionally substituted with halogen or replaced with halogen,

$R^3$  =  $C_{2-4}$ alkyl, optionally substituted with halogen,

$R^4$  =  $SO_2NR^5R^6$ ,

$C_{1-4}$ alkyl, optionally substituted with  $NR^5R^6$ , CN,  $CONR^5R^6$ ,  $CO_2R^7$ , or halogen,

C<sub>2-4</sub>-alkenyl, optionally substituted with NR<sup>5</sup>R<sup>6</sup>, SONR<sup>5</sup>R<sup>6</sup>, CONR<sup>5</sup>R<sup>6</sup>, CO<sub>2</sub>R<sup>7</sup>, or halogen,

C<sub>2-4</sub>-alkanoyl, optionally substituted with NR<sup>5</sup>R<sup>6</sup>, SONR<sup>5</sup>R<sup>6</sup>, CONR<sup>5</sup>R<sup>6</sup>, CO<sub>2</sub>R<sup>7</sup>, or halogen,

R<sup>5</sup> and R<sup>6</sup>, independent of one another, represent hydrogen or C<sub>1-4</sub>alkyl, or, together with the nitrogen atom to which they are attached, represent a pyrrolidino, piperidino, morpholino, 4-(NR<sup>8</sup>)-1-piperazinyl or 1-imidazolyl ring which, optionally, may be substituted with one or two C<sub>1-4</sub>alkyl groups,

R<sup>7</sup>=hydrogen or C<sub>1-4</sub>alkyl, optionally, substituted with fluorine, and

R<sup>8</sup>=hydrogen, C<sub>1-3</sub>alkyl, or hydroxy alkyl having 1-4 C atoms, or a pharmaceutically acceptable salt thereof,

wherein the neuropathy is selected from the group consisting of a peripheral diabetic polyneuropathy, gastroparesis, a degenerative neuropathy, a toxic neuropathy, and a metabolic neuropathy.

6. (Cancelled)

7. (Previously presented) The method of claim 5, wherein from 5-50 mg/day of said pharmaceutical agent is administered to a patient being treated.

8. (Previously presented) The method of claim 5, wherein from 25-50 mg/day of said pharmaceutical agent is administered to a patient being treated.

9. (Cancelled)

10. (Cancelled)

11. (Cancelled)


12. (Cancelled)

13. (Cancelled)

14. (Cancelled)

15. (New) The method of claim 5 wherein the neuropathy is selected from the group consisting of gastroparesis, a degenerative neuropathy, a toxic neuropathy, and a metabolic neuropathy.

16. (New) A method for a chemotherapeutic treatment of a peripheral diabetic polyneuropathy consisting of application to a patient in need thereof from 1-100 mg/day of a pharmaceutical agent comprising a compound of formula (I):



in which

$R^1$ =C<sub>1-6</sub>alkyl, optionally substituted with halogen,

$R^2$ =hydrogen or C<sub>1-4</sub>alkyl, optionally substituted with halogen or replaced with halogen,

$R^3$ =C<sub>2-4</sub>alkyl, optionally substituted with halogen,

$R^4$ =SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>,

C<sub>1-4</sub>alkyl, optionally substituted with NR<sup>5</sup>R<sup>6</sup>, CN, CONR<sup>5</sup>R<sup>6</sup>, CO<sub>2</sub>R<sup>7</sup>, or halogen,

C<sub>2-4</sub>-alkenyl, optionally substituted with NR<sup>5</sup>R<sup>6</sup>, SONR<sup>5</sup>R<sup>6</sup>, CONR<sup>5</sup>R<sup>6</sup>, CO<sub>2</sub>R<sup>7</sup>, or halogen,

C<sub>2-4</sub>-alkanoyl, optionally substituted with NR<sup>5</sup>R<sup>6</sup>, SONR<sup>5</sup>R<sup>6</sup>, CONR<sup>5</sup>R<sup>6</sup>, CO<sub>2</sub>R<sup>7</sup>, or halogen,

R<sup>5</sup> and R<sup>6</sup>, independent of one another, represent hydrogen or C<sub>1-4</sub>alkyl, or, together with the nitrogen atom to which they are attached, represent a pyrrolidino, piperidino, morpholino, 4-(NR<sup>8</sup>)-1-pipera-

zinyll or 1-imidazolyl ring which, optionally, may be substituted with one or two C<sub>1-4</sub>alkyl groups,

R<sup>7</sup>=hydrogen or C<sub>1-4</sub>alkyl, optionally, substituted with fluorine, and

R<sup>8</sup>=hydrogen, C<sub>1-3</sub>alkyl, or hydroxy alkyl having 1-4 C atoms, or a pharmaceutically acceptable salt thereof.